Buprenorphine Use: The International Experience
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The confluence of the heroin injection epidemic and the human immunodeficiency virus (HIV) infection epidemic has increased the call for expanded access to effective treatments for both conditions. Buprenorphine and methadone are now listed on the World Health Organization's Model Essential Drugs List. In France, which has the most extensive experience, buprenorphine has been associated with a dramatic decrease in deaths due to overdose, and buprenorphine diversion appears to be associated with inadequate dosage, social vulnerability, and prescriptions from multiple providers. Other treatment models (in the United States, Australia, Germany, and Italy) and buprenorphine use in specific populations are also reviewed in the present article. In countries experiencing a dual epidemic of heroin use and HIV infection, such as former states of the Soviet Union and other eastern European and Asian countries, access to buprenorphine and methadone may be one potential tool for reducing the spread of HIV infection among injection drug users and for better engaging them in medical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S., Turner, B. J., Eggan, F., Beckman, R., Vitiello, B., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.721 · Cited by 1,255 · cited 1×
“In a representative US sample of adults receiving HIV care, nearly half screened positive for depression and other psychiatric comorbidities [170].”
BackgroundJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“) prenorphine alone [49], the extent to which the combination formulation is likely to mitigate abuse or diversion of buprenorphine may be limited [39].”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“and short-term medical withdrawal, and has bioavailability at least comparable to that of buprenorphine alone [54-59].”
BackgroundKakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · cited 1×
“full opioid /A-receptor agonists, buprenorphine, a partial ,ureceptor agonist and K-receptor antagonist, represents a valid treatment option for managing opioid dependence and a burgeoning HIV infection prevention strategy [36-38], supported by extensive studies [39-46].”
BackgroundBuprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 1×
“full opioid /A-receptor agonists, buprenorphine, a partial ,ureceptor agonist and K-receptor antagonist, represents a valid treatment option for managing opioid dependence and a burgeoning HIV infection prevention strategy [36-38], supported by extensive studies [39-46].”
BackgroundBuprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“Buprenorphine appears to have antidepressant effects [180] that may be attributable to its pharmacological profile as a partial m-agonist and k-antagonist.”
BackgroundPain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent
Compton, P., Charuvastra, V. C., & Ling, W. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00200-3 · Cited by 311
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“as 75% experienced relapse within 6 months of discharge from inpatient care in one study [119].”
BackgroundSublingual Buprenorphine Is Effective in the Treatment of Chronic Pain Syndrome
Malinoff, H. L., Barkin, R. L., & Wilson, G. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000160935.62883.ff · Cited by 121 · cited 1×
“Interestingly, laboratory and open-label uncontrolled clinical evaluations suggest that buprenorphine can produce an antihyperalgesic state [143] and therefore could be helpful in the management of opioid-dependent patients with chronic, nonmalignant pain [144, 145].”
Background
Cited by
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Kocherlakota, P. (2014) · Pediatrics · doi:10.1542/peds.2013-3524 · Cited by 612
Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104010028 · Cited by 398
Confronting the Stigma of Opioid Use Disorder—and Its Treatment
Olsen, Y., & Sharfstein, J. M. (2014) · JAMA · doi:10.1001/jama.2014.2147 · Cited by 306
Metadata
- Authors
- Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-15
- Volume
- 43
- Issue
- Supplement 4
- Pages
- S197-S215
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2121538801
- Cited by
- 141
- References
- 12
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine Use: The International Experience. https://app.cochat.ai/papers/10.1086/508184
- The paper
- Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E. (2006). Buprenorphine Use: The International Experience. Clinical Infectious Diseases. https://doi.org/10.1086/508184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.